SMAD4 and pachyonychia congenita: A loss of SMAD4 expression is observed in about half of all patients diagnosed with PC and it has been hypothesized that SMAD4 inactivation is associated with a worse prognosis and with the pattern of disease recurrence/metastatic progression in localised PC [6,7,8].